Meeder Asset Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Meeder Asset Management’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-408	Closed	-$59K	–	2479
2022 Q2	$59K	Buy	+408	New	+$52.1K	﹤0.01%	837
2022 Q1	–	Sell	-914	Closed	-$125K	–	2618
2021 Q4	$125K	Buy	+914	New	+$116K	0.01%	376
2019 Q3	–	Sell	-2,506	Closed	-$109K	–	2379
2019 Q2	$109K	Buy	+2,506	New	+$141K	0.01%	735
2017 Q3	–	Sell	-141	Closed	-$4K	–	1893
2017 Q2	$4K	Buy	+141	New	+$3.25K	﹤0.01%	1305

Other funds holding BHVN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SFM

Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Meeder Asset Management's BHVN Position: Q3 2022 in Review

Meeder Asset Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2022, closing a stake of 408 shares — an estimated $59K sold.

Meeder Asset Management first reported a position in BHVN in Q2 2017 and held it in 4 quarters. The position peaked at $125K in Q4 2021. 240 funds tracked by Wall St. Rank hold BHVN as of Q3 2022.

Meeder Asset Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2022 after selling out during the quarter.
Meeder Asset Management sold 408 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2022, an estimated $59K.
Meeder Asset Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2017 and held it in 4 quarters.
Meeder Asset Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $125K in Q4 2021.
240 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2022.

Based on Meeder Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.